Mental health · Massachusetts
Mental health studies in Massachusetts
84 studies have at least one recruiting site in Massachusetts. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
84 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Boston, MA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Boston, MA + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Boston, MA + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Watertown, MA + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Boston, MA + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Boston, MA + 33 other US sites
- Eligibility basics
- Ages 18–74
- Recruiting
SAINT in Postpartum Depression (PPD)
Magnus Medical
- Location
- Worcester, MA + 3 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Watertown, MA + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Boston, MA + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Boston, MA + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Boston, MA + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Methuen, MA + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Boston, MA + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Belmont, MA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Worcester, MA + 36 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Home-Based tDCS Treatment Of Major Depressive Disorder
Sooma Medical Inc
- Location
- Boston, MA
- Eligibility basics
- Ages 22–70
- RecruitingPhase 2
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Russells Mills, MA + 20 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Worcester, MA + 22 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Boston, MA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of NTX-1472 in Social Anxiety Disorder
Newleos Therapeutics, Inc.
- Location
- Boston, MA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Springfield, MA + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Monument Therapeutics Limited
- Location
- Boston, MA + 14 other US sites
- Eligibility basics
- Ages 17–30
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
atai Therapeutics, Inc.
- Location
- Springfield, MA + 33 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Watertown, MA + 20 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.